Levetiracetam XR (Keppra XR) – A Quick Reference Guide
| Topic | Details |
|-------|---------|
| Generic name | Levetiracetam |
| Brand name (XR) | Keppra XR (extended‑release) |
| Class | Antiepileptic drug (AED), pyrrolidone derivative |
| Form | Tablet – 500 mg, 750 mg, 1 g, 1.5 g, 2 g |
| Release mechanism | Micro‑encapsulated, polymer‑coated, sustained‑release (delivers ~70 % over 24 h) |
| Indications | • Partial‑onset seizures (single‑tonic/tonic‑clonic or complex partial) in adults and ≥ 12‑year‑olds
• Adjunctive therapy for generalized tonic‑clonic seizures in adults (when used with other AEDs) |
| Not for | • Status epilepticus (use IV levetiracetam or other agents)
• Acute seizure emergencies |
---
How It’s Taken
| Age group | Typical starting dose | Titration | Maintenance dose (adult) |
|-----------|-----------------------|-----------|--------------------------|
| Adults (≥ 18 yr) | 500 mg BID (or 1000 mg/day if using IR) | Increase 500 mg every 1–2 weeks, up to 4000 mg/day (max) | 2000–4000 mg/day, titrated to response |
| Children 12–17 yr | 20 mg/kg/day (max 2000 mg/day) | Same titration as adults | 1000–2000 mg/day |
| Children 2–11 yr | 10–20 mg/kg/day (max 2000 mg/day) | Same | 500–2000 mg/day |
Take with or without food. Do not split the tablet unless the doctor instructs, as it will alter the release profile.
---
Pharmacokinetics (Key Points)
| Property | XR Profile |
|----------|------------|
| Absorption | ~70 % of the dose released over 24 h; peak plasma concentration 4–12 h after ingestion |
| Distribution | 65 % protein bound (mainly albumin) |
| Metabolism | Minimal hepatic metabolism (no significant CYP450 interaction) |
| Elimination | Renally excreted unchanged; 30–40 % in urine, 40–50 % in feces |
| Half‑life | 8–11 h (similar to IR but more constant) |
---
Contraindications & Precautions
| Category | Details |
|----------|---------|
| Contraindications | • Severe renal impairment (eGFR < 15 mL/min/1.73 m²) – dose adjustments or IR preferred
• Known hypersensitivity to levetiracetam |
| Precautions | • Renal impairment – reduce dose (e.g., 500 mg BID in CKD stage 3)
• Pregnancy – Category B (animal studies show no teratogenicity); use only if benefits outweigh risks
• Lactation – excreted in breast milk; not recommended
• Mood/behavior – risk of agitation, depression, suicidal ideation (especially in children) – monitor closely
• Rash – severe rash (Stevens–Johnson) reported in < 1 % of patients, especially in kids |
---
Common Side Effects (Incidence < 10 %)
| Symptom | Notes |
|---------|-------|
| Dizziness | May impair driving or operating machinery |
| Somnolence / Fatigue | Rare; more common in older adults |
| Headache | Mild to moderate |
| Irritability / Anxiety | More common in adolescents |
| Nausea / Vomiting | Usually self‑limited |
| Rash | Monitor; treat promptly if severe |
| Elevated liver enzymes | Very rare; usually transient |
---
Serious but Rare Adverse Events
| Event | Frequency | Action |
|-------|-----------|--------|
| Suicidal thoughts / behavior | < 0.1 % | Immediate medical evaluation |
| Severe rash (Stevens–Johnson/ TEN) | < 0.01 % | Discontinue and treat emergently |
| Elevated blood pressure | < 0.5 % | Monitor BP regularly |
| Renal toxicity | < 0.1 % | Monitor creatinine & eGFR |
---
Drug Interactions
| Drug | Interaction | Clinical Significance |
|------|-------------|-----------------------|
| Other AEDs (e.g., phenytoin, carbamazepine, valproate) | No major interaction | May affect seizure control; monitor efficacy |
| CYP3A4 inhibitors/inducers | None | Minimal |
| Lithium | None | No dose change |
| Statins | None | No dose change |
| Alcohol | May enhance CNS depression | Use cautiously |
Tip: While levetiracetam is considered “clean” regarding drug‑drug interactions, always review the complete medication list with a clinician, especially when adding high‑dose or novel therapies.
---
Patient Counseling Points
1. Take as prescribed – never skip doses; missing one may increase seizure risk.
2. Do not abruptly stop – taper under medical supervision to avoid rebound seizures.
3. Watch for mood changes – report any new depression, irritability, or suicidal thoughts.
4. Report rashes – especially if it covers a large area or is accompanied by fever.
5. Avoid driving if you feel drowsy or dizzy until you know how you react.
6. Kidney health matters – keep blood tests (creatinine, eGFR) up to date.
7. Pregnancy & breastfeeding – discuss risks with your doctor before conception or if you are nursing.
8. Keep medication safe – out of reach of children; store at room temperature, away from moisture.
---
How It Differs from Levetiracetam IR (Keppra)
| Feature | Keppra XR (Extended‑Release) | Keppra (Immediate‑Release) |
|---------|--------------------------------|-----------------------------|
| Form | Tablet | Capsule |
| Release | Sustained over 24 h | Rapid,